Form 8-K - Current report:
SEC Accession No. 0001193125-26-073377
Filing Date
2026-02-26
Accepted
2026-02-26 07:05:13
Documents
13
Period of Report
2026-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d119012d8k.htm   iXBRL 8-K 23996
2 EX-99.1 d119012dex991.htm EX-99.1 98102
  Complete submission text file 0001193125-26-073377.txt   250221

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA phat-20260226.xsd EX-101.SCH 2867
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE phat-20260226_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE phat-20260226_pre.xml EX-101.PRE 11272
15 EXTRACTED XBRL INSTANCE DOCUMENT d119012d8k_htm.xml XML 3646
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Filer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39094 | Film No.: 26681660
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)